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Abstract Children/adolescents with attention-deficit/hy-
peractivity disorder (ADHD) may have a poor or inadequate
response to psychostimulants or be unable to tolerate their
side-effects; furthermore, stimulants may be inappropriate
because of co-existing conditions. Only one non-stimulant
ADHD pharmacotherapy, the noradrenaline transporter
inhibitor atomoxetine, is currently approved for use in
Europe. We review recent advances in understanding of the
pathophysiology of ADHD with a focus on the roles of
catecholamine receptors in context of the a2A-adrenergic
receptor agonist guanfacine extended release (GXR), a new
non-stimulant treatment option in Europe. Neuroimaging
studies of children/adolescents with ADHD show impaired
brain maturation, and structural and functional anomalies in
brain regions and networks. Neurobiological studies in
ADHD and medication response patterns support involve-
ment of monoaminergic neurotransmitters (primarily
dopamine and noradrenaline). Guanfacine is a selective
a2A-adrenergic receptor agonist that has been shown to
improve prefrontal cortical cognitive function, including
working memory. The hypothesized mode of action of
guanfacine centres on direct stimulation of post-synaptic
a2A-adrenergic receptors to enhance noradrenaline neuro-
transmission. Preclinical data suggest that guanfacine also
influences dendritic spine growth and maturation. Clinical
trials have demonstrated the efficacy of GXR in ADHD, and
it is approved as monotherapy or adjunctive therapy to
stimulants in Canada and the USA (for children and ado-
lescents). GXR was approved recently in Europe for the
treatment of ADHD in children and adolescents for whom
stimulants are not suitable, not tolerated or have been shown
to be ineffective. GXR may provide particular benefit for
children/adolescents who have specific co-morbidities such
as chronic tic disorders or oppositional defiant disorder (or
oppositional symptoms) that have failed to respond to first-
line treatment options.
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Key Points
Psychostimulants and the non-stimulant atomoxetine
increase the extracellular availability of dopamine
and noradrenaline at the synaptic cleft. Although
methylphenidate is generally the first choice
medication for children/adolescents with attention
deficit/hyperactivity disorder (ADHD) in Europe,
stimulants can be unsuitable for some patients.
Guanfacine is a selective a2A-adrenergic receptor
agonist that acts directly on a2A-adrenergic
receptors to enhance noradrenaline
neurotransmission; preliminary evidence suggests
that guanfacine also influences dendritic spine
plasticity in the prefrontal cortex.
Guanfacine extended-release (GXR) is a new non-
stimulant pharmacotherapy for ADHD in Europe for
children and adolescents for whom stimulants are not
suitable, not tolerated or have been shown to be
ineffective. The selective mode of action of GXR
may provide particular benefit for children/
adolescents who have specific co-morbidities such as
chronic tic disorders or oppositional defiant disorder
(or oppositional symptoms) that have failed to
respond to first-line treatment options.
1 Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
complex and multifactorial neurodevelopmental disorder
[1] that is characterized by age-inappropriate and excessive
levels of inattention, hyperactivity and impulsivity [2].
ADHD affects approximately 5 % of children and adoles-
cents worldwide [3, 4] and symptoms persist into adult-
hood in most cases [5]. The disorder is associated with
deficits in executive function [6], including working
memory [7], and leads to impairment in a broad range of
academic and social activities [2]. Emotional dysregulation
is increasingly recognized as a common feature of ADHD,
and may manifest as extreme irritability, frustration, reac-
tive aggression and temper outbursts [8, 9]. Common
ADHD co-morbidities include oppositional defiant disorder
(ODD), conduct disorder and chronic tic disorders includ-
ing Tourette’s syndrome [10, 11].
Although understanding of the pathophysiology of
ADHD has improved greatly in the past decade, treatment
options are still limited. The management of ADHD
comprises non-pharmacological interventions, such as
behavioural therapy, and pharmacotherapy [12–14]. The
psychostimulants methylphenidate (MPH) and
amphetamines were the only available ADHD medications
for many years. Stimulants have a good effect size
(0.8–1.5) [15, 16], and MPH is generally recommended in
Europe as the first choice medication for children/adoles-
cents with ADHD [2, 13]. However, approximately 30 %
of children/adolescents with ADHD are unresponsive to a
single stimulant medication and approximately 10 % fail to
respond to any stimulants [17, 18]. Others are intolerant of
the side effects of stimulants [19, 20]. Moreover, stimulants
may not be the treatment of choice because of a personal or
family history of medical conditions, risks of drug diver-
sion or substance abuse, or parental preference [19, 21, 22].
One non-stimulant pharmacotherapy for ADHD, the
noradrenaline transporter inhibitor atomoxetine (ATX), is
currently approved for use in Europe. The efficacy of ATX
in ADHD is well established [23], but potential clinical
limitations include a delayed onset of action [24] and
sympathomimetic cardiovascular side effects, which are
similar to those of stimulants [25]. An alternative non-
stimulant medication, particularly one without sympath-
omimetic cardiovascular side effects, could provide a
useful therapeutic option for children/adolescents with
ADHD. Guanfacine extended release (GXR; Intuniv) is
approved for the treatment of ADHD as monotherapy or
adjunctive therapy to stimulants in Canada and the USA
(for children and adolescents, 6–17 years) [26, 27]. GXR
was approved recently in Europe as part of a comprehen-
sive programme for the treatment of ADHD in children and
adolescents for whom stimulants are not suitable, not tol-
erated or have been shown to be ineffective [28].
Here we provide an overview of recent advances in our
understanding of the pathophysiology of ADHD in the
context of GXR. This article is intended to provide a
clinical perspective on the neurobiology of ADHD and
mode of action of pharmacotherapies. Given the broad
scope of this article, a formal systematic literature review
was not feasible. Rather, we used our combined clinical
experience to develop an up-to-date and practical narrative
review providing information on ADHD and pharmaco-
logical treatment options, with a focus on clinically rele-
vant recent research findings.
2 Methods of Literature Search
Electronic literature searches via MEDLINE/PubMed were
conducted for articles published in English (unlimited by
date of publication). Combinations of keywords were used
to identify relevant articles, including: ‘Attention deficit
disorder with hyperactivity’, ‘ADHD’, ‘ADD’, ‘patho-
physiology’, ‘neurobiology’, ‘neurochemistry’, ‘imaging’,
‘alpha 2A agonists’, ‘guanfacine’, ‘guanfacine extended
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release’, ‘GXR’, ‘mechanism’, ‘psychostimulants’,
‘methylphenidate’, ‘amphetamine’, ‘atomoxetine’, ‘con-
traindicated’, ‘adverse events’, ‘side effects’, ‘cardiovas-
cular disease’, ‘hypertension’, ‘juvenile hypertension’,
‘tics’, ‘Tourette’s syndrome’, ‘conduct disorder’, ‘opposi-
tional defiant disorder’ and ‘oppositional symptoms’. The
last electronic searches were conducted on 15 July 2015.
Meta-analyses, systematic and narrative reviews, and
original research articles were included. Criteria for each
search were adapted according to the initial number of hits.
Formal literature searches were also supplemented with
key publications, abstracts and posters that were known to
the authors.
3 Pathophysiology of Attention-Deficit/
Hyperactivity Disorder (ADHD)
Although involvement of the prefrontal cortex (PFC) in
ADHD has long been recognized, ADHD is now consid-
ered to be a neurodevelopmental disorder that affects the
whole brain. The PFC regulates high-order cognitive
functions, including attention, behaviour, planning and
emotion through working memory [29]. These executive
functions involve extensive neural network connections
(Fig. 1) [29]. Recent evidence from systems neuroscience-
based studies has demonstrated the importance of circuitry
and connectivity involving large-scale neural networks in
ADHD [30–32]. Accordingly, our understanding of the
pathophysiology of ADHD has changed from a model
based on specific regional differences to widespread altered
connectivity in the whole brain [33].
3.1 Neuroimaging
Recent advances in neuroimaging have allowed the use of
innovative high-resolution computational techniques to
identify anatomical and functional anomalies in ADHD.
Initial magnetic resonance imaging (MRI) studies in ADHD
focused on the morphology of discrete brain regions,
whereas more recent investigations have evaluated altered
connectivity in large-scale neural networks [32, 34, 35].
Neuroanatomical differences between the brains of
individuals with ADHD and healthy controls are well
established [33]. Longitudinal and cross-sectional struc-
tural neuroimaging data indicate that ADHD is character-
ized by a global delay in brain maturation [30, 36, 37].
Cerebral, cerebellar, grey and white matter volumes are
significantly smaller (2.5–4 %) among children/adoles-
cents with ADHD compared with normal controls [30, 37,
38]. Peak cortical thickness is reached significantly later
among children/adolescents with ADHD than normal
controls (10.5 vs. 7.5 years; p\ 1.0 9 10–20) and the
delay is most profound in the lateral PFC (Fig. 2) [36]. A
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Fig. 1 Regulation of attention,
behaviour and emotion through
extensive network connections
of the prefrontal cortex with
other brain regions. Reproduced
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2012;51:356–67,  (2012) with
permission from Elsevier
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persistently smaller volume of the superior cerebellar ver-
mis has also been reported in children/adolescents with
ADHD versus normal controls, and the development tra-
jectory of the cerebellum may be associated with clinical
outcome [39]. Morphological and volumetric changes of
subcortical structures, including the thalamus, basal gan-
glia and limbic system have also been reported [30, 40–42].
The functional significance of these differences in sub-
cortical structures remains unclear but may represent dis-
ruption to neural network architecture in ADHD [41].
MRI studies using tractography 3D-modelling tech-
niques have identified altered structural connectivity in
white matter tracts among children with ADHD. Diffusion
tensor imaging (DTI) provides quantitative data on the
integrity of white matter tracts. Reduced volume and
integrity of white matter tracts between the thalamus and
striatum, hippocampus and PFC have been demonstrated in
children with ADHD versus controls [42]. A meta-analysis
of data from DTI studies (n = 15) suggests that the most
consistent alterations in white matter integrity may be
found in the right anterior corona radiata, right forceps
minor, bilateral internal capsule and left cerebellum [43].
Abnormal connectivity and microstructural integrity in
white matter linking the frontal lobe, striatum and cere-
bellum in children/adolescents with ADHD have also been
demonstrated [44]. Moreover, in this study the altered
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Fig. 2 Attention-deficit/hyperactivity disorder (ADHD) is character-
ized by a delay in cortical maturation: a dorsal view and b right lateral
view. View of the cortical regions where peak thickness was attained
at each age (a 7–12 years, b 7–13 years) in ADHD (upper rows) and
typically developing controls (lower rows). Darker colours indicate
regions where a quadratic model was not appropriate (and thus a peak
age could not be calculated), or the peak age was estimated to lie
outside the age range covered. Both groups showed similar sequences
of regions that attained peak thickness, but the ADHD group showed
considerable delay in reaching this developmental marker. Repro-
duced with permission from Shaw et al. Attention-deficit/hyperactiv-
ity disorder is characterized by a delay in cortical maturation. Proc
Natl Acad Sci USA. 2007;104:19649–54.  (2007) National
Academy of Sciences, USA
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Network dysfunction in ADHD has been examined
systematically using functional neuroimaging. Widespread
differences in functional activation between patients with
ADHD and normal controls have been described and
suggest distinct domain-specific neurofunctional deficits
[32, 38, 45]. Functional MRI (fMRI) provides a measure of
the activity of neural regions involved at rest or during a
particular task [33]. Meta-analyses of fMRI data have
shown consistent right fronto-striatal dysfunction during
inhibition- and attention-related tasks among patients with
ADHD [46]. Attention tasks (data sets n = 13) involved
the dorsolateral PFC, parietal and cerebellar areas. Inhibi-
tion tasks (data sets n = 21) involved the inferior frontal
cortex, supplementary motor area and anterior cingulate
cortex. A further meta-analysis of data from fMRI studies
(n = 11) showed hypoactivation in the left fronto-parieto-
cerebellar areas during timing tasks in ADHD [45].
Recent data indicate that ADHD is associated with
dysfunction in large-scale neural networks, including the
default-mode network (DMN) [31, 32]. The DMN
describes a distinctive set of reciprocally oscillating brain
regions that, in normal controls, are active during the
resting state and suppressed during goal-directed tasks
[47]; in contrast, task-specific neural activity during goal-
directed tasks is reduced in patients with ADHD [46].
Resting-state fMRI data have shown dysfunctional con-
nectivity in the DMN in affected children/adolescents and
adults versus controls, which supports the hypothesis that
ADHD is related to delayed or disrupted maturation of the
DMN [31, 32, 35, 48–50]. A comprehensive meta-analysis
of fMRI studies (n = 55) showed evidence of dysfunction
in the DMN and multiple other neuronal systems involved
in high-level cognitive functions (executive function and
attention) [31]. Moreover, recent data demonstrate altered
connectivity in the DMN and other large-scale networks,
and structural abnormalities in the dorsolateral PFC and
anterior cingulate cortex [32]. Importantly, this modality-
spanning study provides evidence of spatial correspon-
dence in the pattern of structural and functional alterations
in ADHD [32].
3.2 Neurochemistry
Dysregulated early brain network development (aberrant
apoptosis, neurogenesis, neuritogenesis and synaptogene-
sis) may cause an imbalance in dopamine, noradrenaline
and other neurotransmitter systems [51, 52]. Although
animal models do not exactly match ADHD, they provide a
useful method of studying the molecular pathophysiology
of this complex neurodevelopmental disorder [53]. The
spontaneously hypertensive rat (SHR) is considered to be
the most valid available animal model for ADHD; others,
including the Coloboma mouse and actin depolymerizing
factor and n-cofilin double mutant mouse models, also
provide good approximations. Recent advances in imaging
modalities, such as positron emission tomography (PET)
and magnetic resonance spectroscopy, have enabled
investigation of the neurochemistry of ADHD in humans.
3.2.1 Dopamine and Noradrenaline
Dysregulation of monoaminergic neurotransmitter systems,
primarily dopamine and noradrenaline, is hypothesized to
play a central role in the pathophysiology of ADHD [33].
Involvement of the dopaminergic system is highlighted by
the validity of neonatal 6-hydroxy-dopamine lesioned rats
and dopamine transporter (DAT) knockout mice as ADHD
models [54]. The SHR model has reduced levels of c-
aminobutyric acid (GABA), which interacts with both the
dopaminergic and adrenergic systems in the hippocampus
[55]. Alpha2A-adrenergic receptors in the dorsolateral PFC
are involved in the regulation of locomotor hyperactivity in
primates [56]. Dysregulated dopamine metabolism among
treatment-naı¨ve young adults with ADHD has been
demonstrated in a PET study using a radiolabelled dopamine
precursor [57]. Furthermore, PET imaging of treatment-
naı¨ve adult humans with ADHD has shown a reduction in
dopamine (D2/D3) receptors in the caudate and limbic
system, which correlates with symptoms of inattention [58].
Dopamine and adrenergic receptors are members of the G
protein-coupled receptor superfamily of membrane proteins.
Dopamine receptors may be classified as either D1 (D1 and
D5 subtype) or D2 (D2, D3 and D4 subtype) receptors [59,
60]. Adrenergic receptors mediate physiological responses
to adrenaline and noradrenaline. Alpha and b adrenergic
receptors are recognized and each has several subtypes [61–
63]. a1-Adrenergic receptors are primarily located in
smooth muscle, whereas a2-adrenergic receptors are found
predominantly in the central nervous system (CNS) and
peripheral sympathetic nervous system. Three distinct sub-
types of human a2-adrenergic receptors (a2A-, a2B- and
a2C-) have been identified [61, 64, 65]. Alpha2B-adrenergic
receptors are most prevalent in the thalamus, whereas a2A-
and a2C-adrenergic receptors are widespread throughout the
brain [66, 67]. The a2A-adrenergic receptor is the most
common subtype found in the PFC [68].
In the PFC, a2A-adrenergic and D1 receptors are loca-
ted predominantly on the dendritic spines of pyramidal
neurons [69, 70]. Dendritic spines are tiny protrusions from
a neuronal dendrite that interconnect via glutaminergic
synapses with other pyramidal neurons in the PFC to form
complex neural networks [29]. Noradrenaline and dopa-
mine powerfully modulate network connectivity through
their effects on a2A-adrenergic and D1 receptors on den-
dritic spines [29]. Imbalances in the fine-tuning of pyra-
midal neurons by noradrenaline and/or dopamine in the
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PFC affect information processing and are believed to
underlie the symptoms of ADHD.
Stimulation of D1 receptors by dopamine is believed to
increase the production of cyclic adenosine monophos-
phate (cAMP), thereby opening hyperpolarization-acti-
vated cyclic nucleotide-gated (HCN) cation channels near
the synapse (Fig. 3) [71]. An open channel causes the
signal to ‘leak out’, thus shunting inputs out of the den-
dritic spine [72] and weakening network connections [73].
Conversely, stimulation of a2A-adrenergic receptors by
noradrenaline inhibits cAMP signalling, thereby closing
HCN channels [72]. Closure of the channel allows the
signal to be conducted down the pyramidal neuron. In
theory, noradrenaline strengthens the appropriate ‘signal’
between neurons with shared inputs, whereas dopamine
reduces ‘noise’ by dissipating inappropriate network con-
nections [72]. Thus, dopamine and noradrenaline have
contrasting but complementary actions to increase the
‘signal-to-noise ratio’ in the PFC [72].
Moderate stimulation of a2A-adrenergic receptors in the
PFC improves working memory in animal models and
humans [69, 74, 75]. Similarly, moderate stimulation of D1
receptors in the PFC enhances working memory perfor-
mance [71]. Both noradrenaline and dopamine concentra-
tions in the synaptic cleft have an ‘inverted U-shaped’
effect on working memory, in which too much or too little
of either neurotransmitter impairs PFC function (Fig. 4)
[73]. Excessive levels of noradrenaline at the synapse leads
to binding of noradrenaline to other adrenergic receptor
subtypes on distant synapses and impairs working memory
[73]. Likewise, excessive levels of dopamine may result in
the recruitment of other dopamine receptor subtypes [73].
3.2.2 Other Neurotransmitters
ADHD probably results from interplay between several
dysfunctional neurotransmitter systems. Another
monoaminergic neurotransmitter, serotonin, is postulated
When HCN channels are closed, synaptic inputs
are conducted and network activity increased.
Thus, “signal” is strengthened by the action of
noradrenaline on 2A-adrenergic receptor
nepolennahcNCHdesolclennahcNCH
When HCN channels are open, synaptic inputs
are shunted out and network activity reduced.
Thus, “noise” is suppressed by the action of



















Fig. 3 Noradrenaline and dopamine modulate the strength of
network connections at dendritic spines in the prefrontal cortex to
influence information processing. Methylphenidate (MPH) primarily
blocks the dopamine transporter; amphetamines (AMPs) block the
dopamine and noradrenaline transporters, and increase output of
dopamine; atomoxetine (ATX) blocks the noradrenaline transporter.
Guanfacine (G) directly stimulates postsynaptic a2A-adrenergic
receptors and thereby closes hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels in the post-synaptic neuron and
enhances noradrenaline neurotransmission. Adapted from Wang M
et al. Alpha2A-adrenoceptors strengthen working memory networks
by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell.
2007;129:397–410  (2007) with permission from Elsevier and
Arnsten AF, Rubia K. Neurobiological circuits regulating attention,
cognitive control, motivation, and emotion: disruptions in neurode-
velopmental psychiatric disorders. J Am Acad Child Adolesc
Psychiatry. 2012;51:356–67,  (2012) with permission from Elsevier
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to play a role in ADHD. Paediatric major depressive dis-
order and paediatric obsessive compulsive disorder share
some neuropsychological deficits and affected neural cir-
cuits with ADHD [29]. Selective serotonin re-uptake
inhibitors are an effective treatment for these two disorders
and it has been suggested that they act to normalize sero-
tonergic regulation of emotion and inhibitory control [29].
Moreover, 5HT1B knockout mice exhibit hyperactivity,
and attention- and sensation-seeking behaviour [76].
Association studies have identified links between various
serotonergic genes and ADHD and there may be a partic-
ular association between the serotonin receptor gene,
HTR1B, and the inattentive subtype of ADHD [77].
Recent evidence suggests that dysfunction in the gluta-
matergic neurotransmitter system plays a role in the
pathophysiology of ADHD [78]. Glutamate is the main
excitatory neurotransmitter in the human brain, and a key
neuronal growth factor [79]; the glutamate N-methyl-D-
aspartate (NMDA) receptor NR2 subunit controls synaptic
plasticity and memory function during brain development
[80]. In vivo data indicate that the glutamatergic system is
hyperfunctional in the PFC of the SHR [81]. In addition,
increased glutamatergic tone in children with untreated
ADHD versus controls [82] and effects on glutamatergic
systems following pharmacotherapy have been detected in
magnetic resonance spectroscopy studies [83, 84]. Recent
data suggest that glutamine levels may be increased among
children (but not adults) with ADHD versus controls [85].
Preliminary data suggest that histamine may also be
associated with ADHD. Histaminergic pathways are asso-
ciated with arousal, learning and memory [86–88]. His-
tamine H3 receptor antagonists improve the performance
of the SHR in inhibitory avoidance tasks, thus suggesting a
tentative role in the treatment of ADHD [89, 90]. In
addition, MPH and ATX are reported to increase histamine
release in the PFC of the SHR [89, 91, 92].
3.3 Genetics
The pathophysiology of ADHD has a strong genetic
component [93]. Heritability of the disorder is estimated to
range from 60 to 80 % [93]. Candidate gene studies have
also shown a number of gene variants to be associated with
ADHD, including those coding for synaptosomal-associ-
ated protein 25 (SNAP-25), dopamine receptors (DRD4)
and the DAT (DAT1) [94]. Pooled molecular genetics data
support the involvement in genes coding for regulators of
synaptic plasticity, including CTNNA2 and KALRN, and
cell adhesion molecules in ADHD [95]. However, each
gene variant is likely to contribute only a small individual
effect [33]. Complex ‘gene–gene’ and ‘gene–environment’
interactions may explain how individual genes modify the
response to environmental or biological variables [96].
4 Pharmacological Treatment of ADHD
An understanding of the pathophysiology of ADHD and
modes of action of pharmacotherapies may help clinicians
select the medication with the most appropriate efficacy
and safety profile to match the individual needs of each
patient [33]. The complex modes of action of ADHD
pharmacotherapies are not fully understood. Nonetheless,
all empirically effective medications seem to enhance
signalling of dopamine and/or noradrenaline in the CNS
(Table 1) [72]. The stimulants (MPH and amphetamines)
and ATX act indirectly to increase the availability of
noradrenaline and dopamine in the synaptic cleft, whereas
guanfacine has a direct effect on post-synaptic a2A-
adrenergic receptors (Fig. 3).
4.1 a2-Adrenergic Receptor Agonists
Interest in the use of a2-adrenergic receptor agonists for the
treatment of ADHD began 30 years ago [97]. Early studies
focused on immediate-release clonidine and, later, guan-
facine [97, 98]. Clonidine engages equally with all three a2-
adrenergic receptor subtypes, and also binds to imidazoline
I1 receptors [98–100]. In contrast, guanfacine has higher
affinity for the a2A- than a2B- or a2C-adrenergic receptor
subtypes [101, 102]. Indeed, receptor-binding studies have
shown guanfacine to be the most selective a2A-adrenergic
receptor agonist available [103] and is, thus, referred to as a
‘selective’ a2A-adrenergic receptor agonist.
Clinical use of immediate-release clonidine and guan-















NA or DA levels in the PFC
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Fig. 4 Inverted U-shaped influence of noradrenaline (NA) and
dopamine (DA) on the prefrontal cortex (PFC). Both NA and DA
have an ‘inverted U-shaped’ influence on PFC physiology and
cognitive performance; too little or too much of either neurotrans-
mitter impairs PFC function. Adapted with permission from Macmil-
lan Publishers Ltd from Arnsten AF. Stress signalling pathways that
impair prefrontal cortex structure and function. Nat Rev Neurosci.
2009;10:410–22
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[98]. Rapid absorption of immediate-release a2-adrener-
gic receptor agonists leads to high peak plasma concen-
trations that are associated with side-effects such as
sedation and a dry mouth; rapid clearance necessitates
frequent dosing through the day [98, 104]. Extended-re-
lease formulations of guanfacine and clonidine have been
developed to overcome these PK issues. Extended-release
clonidine is approved for the treatment of ADHD as
monotherapy or adjunctive therapy in children/adolescents
in the USA [105]. GXR is approved for the treatment of
ADHD as monotherapy or adjunctive therapy in Canada
and the USA (for children and adolescents) [26, 27], and
was approved recently in Europe as part of a compre-
hensive programme for the treatment of children and
adolescents with ADHD for whom stimulants are not
suitable, not tolerated or have been shown to be ineffec-
tive [28].
4.1.1 Guanfacine Extended Release (GXR)
Guanfacine directly stimulates postsynaptic a2A-adrener-
gic receptors to enhance noradrenaline neurotransmission
(Fig. 3) [98, 106, 107]. The stimulation of a2A-adrenergic
receptors in the PFC produces a beneficial effect on cog-
nitive function. Improvement in attention, working mem-
ory and learning with guanfacine has been demonstrated in
animal studies [74, 106–115]. A beneficial effect of
guanfacine has also been shown on impulsive decision-
making behaviour in rats and impulsive self-injurious
behaviour in rhesus macaques [116–118]. Moreover,
guanfacine (29 lg/kg single dose administered orally)
improved spatial working memory and planning in a dou-
ble-blind, placebo-controlled trial in healthy adults [75].
Guanfacine (1 mg single dose administered orally) has also
been shown to modulate emotional biasing of cognitive
control in healthy adults [119, 120].
fMRI data show that the effect of guanfacine on emo-
tional biasing of cognitive control in healthy adults is
associated with altered functional connectivity between the
right and left amygdala and PFC [120]. Preliminary fMRI
data suggest that clinical response to GXR (1 mg/day
titrated to maximum 4 mg/day) in children/adolescents
with ADHD is associated with reduced activation in the
right midcingulate and left posterior cingulate cortices
[121]. In vivo rat pharmacological MRI data support dif-
fering effects of guanfacine in specific areas of the brain
[122]; functional blood oxygenation level dependent
responses suggest that guanfacine increases neuronal
activity in the frontal cortex but decreases activity in the
basal ganglia (caudate, putamen and nucleus accumbens)
and entorhinal cortex [122].
Three hypotheses, based on in vitro and in vivo animal
model data, have been proposed to explain the underlying
physiological mechanism of action of guanfacine: (1) the
HCN channel and network hypothesis; (2) the excitatory
postsynaptic current (EPSC) network hypothesis; and (3)
the spinogenic hypothesis.
(1) The HCN channel and network hypothesis provides
a short-term mechanism by which a2A-adrenergic receptor
agonists may regulate PFC networks. As previously
described, stimulation of post-synaptic a2A-adrenergic
receptors inhibits the production of cAMP, leading to
closure of HCN channels and strengthening of the func-
tional connectivity of PFC microcircuits. Blockade of HCN
channels in superficial layers (II/III) of the rat PFC
improves working memory performance [69] and guan-
facine strengthens delay-related firing of PFC neurons
during working memory tasks in electrophysiological pri-
mate studies [69].
(2) Stimulation of a2A-adrenergic receptors also sup-
presses excitatory synaptic inputs in pyramidal neurons
[123, 124]. As described above, SHR model data suggest
that the glutamatergic system is hyperfunctional in ADHD
[81]. The EPSC network hypothesis is derived from in vitro
and in vivo studies of rats and suggests that guanfacine
may suppress glutamate transmission in deep layers (V–VI)
Table 1 Summary of the modes of action of stimulant and non-stimulant pharmacotherapies in attention-deficit/hyperactivity disorder (ADHD)
Pharmacotherapy Mechanism of action
Stimulants
Amphetaminea Blocks dopamine and noradrenaline transporters and increases output of dopamine
Methylphenidatea Primarily acts by blocking the dopamine transporter to increase dopamine levels
Non-stimulants
Atomoxetine Blocks the noradrenaline transporter to moderately increase dopamine and noradrenaline levels
Clonidineb Directly stimulates post-synaptic a2A-adrenergic receptors; also binds to other a2-adrenergic receptor subtypes
Guanfacinec Directly stimulates post-synaptic a2A-adrenergic receptors to enhance noradrenaline neurotransmission
a Short- and long-acting formulations are approved for the treatment of ADHD in Europe
b Not approved for the treatment of ADHD in Europe
c Guanfacine immediate release is not approved for the treatment of ADHD
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of the medial PFC via complex intracellular signalling
pathways [123, 124].
Further, it has been proposed that the intracellular
pathways controlling HCN channels and the suppression of
glutamate transmission may be linked [123, 124]. As such,
a2A-adrenergic receptor activation may trigger both
mechanisms, which work together to fine tune the synaptic
inputs of pyramidal cells during different physiological
conditions [123, 124]. It is hypothesized that HCN channel
control (in layers II/III of the PFC) may predominate at low
guanfacine doses, whereas the EPSC network (in layers V–
VI) is principally affected at high doses [69, 123]. Indeed,
neuronal firing in the PFC during working memory tasks is
enhanced by low guanfacine doses and suppressed at high
doses [69], whereas EPSC network effects can be demon-
strated only at relatively high doses [123]. Thus, guan-
facine seems to improve the signal-to-noise ratio in the
PFC predominantly through an effect on HCN channels,
but may also protect it during extreme stress (when nora-
drenaline is excessively released) through effects on the
EPSC network [123].
(3) The spinogenic hypothesis describes a long-term
effect of a2A-adrenergic receptor agonists mediated via
dendritic spines. Dendritic spines can change rapidly in
shape, volume and number [125, 126]. As previously
described, dendritic spine plasticity in the PFC plays a key
role in learning and memory [126]. a2A-adrenergic
receptor agonists, such as guanfacine, increase the length
and density of dendritic spines of cultured mouse cortical
neurons [127, 128]. Guanfacine increases the expression of
synaptic protein PSD95 and promotes the maturation of
dendritic spines of cultured rat cortical neurons [129].
Indeed, recent data show that guanfacine prevents dendritic
spine loss in the PFC and protects working memory per-
formance in rats exposed to chronic stress [115].
a2A-Adrenergic receptor agonists also inhibit sympa-
thetic nervous system activity. Guanfacine stimulates post-
synaptic a2A-adrenergic receptors in the vasomotor centre
of the brainstem to reduce peripheral sympathetic tone, and
may also activate peripheral presynaptic a2A-adrenergic
receptors [130–132]. Overall, guanfacine acts to decrease
heart rate and vascular resistance [133]. Indeed, guanfacine
was originally developed as an immediate-release formu-
lation and clinically utilized as a centrally acting antihy-
pertensive agent [134]. Guanfacine is associated with less
potent hypotensive and sedative effects than is clonidine
[135]. Data from a recent meta-analysis suggest that the
relative risk of fatigue and somnolence is higher with
extended-release clonidine than GXR as monotherapy for
ADHD (10.86 [p = 0.02] and 3.21 [p = 0.0008], respec-
tively, vs placebo) [136]. The selective affinity of guan-
facine for a2A-adrenergic receptors is believed to underlie
the differing physiological effects of these two a2A-
adrenergic receptor agonists [98]. Detailed description of
the pharmacodynamic and pharmacokinetic properties and
posology of GXR are beyond the scope of this review, but
information is available elsewhere for the interested reader
[28, 137, 138].
4.2 Other ADHD Pharmacotherapies
Stimulants (various formulations of short- and long-acting
MPH and amphetamines including lisdexamfetamine
dimesylate) and ATX are approved for the treatment of
ADHD in specific patient populations in many European
countries and other regions. Stimulants and ATX act to
block the re-uptake of dopamine and/or noradrenaline into
the presynaptic neuron. Re-uptake by the presynaptic
noradrenaline (norepinephrine) transporter (NET) is the
main process by which the effects of noradrenaline are
terminated in the CNS [139]. Similarly, dopamine is
cleared from the synaptic cleft by re-uptake via the DAT;
however, in the PFC, dopamine is also recognized by NETs
[140].
Human and primate PET studies indicate that MPH
binds predominantly to DATs in the striatum [141, 142].
Accordingly, the therapeutic effect of MPH in ADHD is
believed to be primarily due to the blockade of DATs,
which increases dopamine levels at the synapse (Fig. 3)
[143, 144]. Preliminary data suggest that MPH may also
downregulate dopamine turnover in children/adolescents
with ADHD [57]. In addition, human PET data suggest
that MPH also binds to NETs, but the clinical relevance
of this is currently unclear [145]. Effects of MPH on
neuronal remodelling in the nucleus accumbens, striatum
and other brain regions have also been demonstrated
[146–148]. Chronic exposure of mice to MPH increases
dendritic spine density [146], and a sustained effect of
MPH on synaptic gene and protein expression and
synaptic and dendritic spine structure has been shown in
rat models [147, 148].
Amphetamines inhibit the re-uptake of dopamine and
noradrenaline from the synaptic cleft and induce an efflux
of dopamine into the synapse in the PFC, striatum and
nucleus accumbens (Fig. 3) [149, 150]. Amphetamines are
a competitive substrate for the re-uptake transporters NET
and DAT [151]. Inside neurons, amphetamines bind with
the vesicular monoamine transporter 2 (VMAT2), thereby
preventing the translocation of monoamines into intraneu-
ronal storage vesicles [151]. Amphetamines also weakly
inhibit monoamine oxidase (particularly monoamine
oxidase A), which reduces intracellular catabolism of
neurotransmitters [152]. As the concentration of
neurotransmitters in the presynaptic neuron increases, the
direction of action of the re-uptake transporter changes
direction causing an efflux into the synapse [151].
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The non-stimulant ATX inhibits NETs to moderately
increase noradrenaline and dopamine levels in the PFC by
indirect action (Fig. 3) [153]. ATX is reported to have no
effect on dopamine efflux in the striatum or nucleus
accumbens [153]. In vitro rodent data suggest that ATX
may also block NMDA receptors on cortical and hip-
pocampal neurons, thus affecting glutamatergic transmis-
sion [154]. A sustained effect of ATX on synaptic mRNA
and proteins involved in neuronal plasticity has been
demonstrated in rats [155], and a preliminary report of
sustained maintenance of clinical response after discon-
tinuation of long-term ATX warrants further investigation
[156]. There seems to be some overlap in the neurophysi-
ological effects of stimulants and ATX. Data from in vitro
and in vivo animal studies suggest that both MPH and ATX
may indirectly stimulate D1 and a2-adrenergic receptors
on post-synaptic neurons in the PFC [157–159]. Human
fMRI and arterial spin labelling MRI data also indicate
common spatial patterns of brain activity after adminis-
tration of MPH and ATX [160, 161].
Stimulants are the most widely prescribed class of
pharmacotherapy for ADHD but may not be suitable for all
children/adolescents [162, 163]. Patients may have a con-
traindication to MPH or amphetamines, or experience
inadequate symptom control or side-effects [17–19, 21].
Common side-effects of stimulant treatment include loss of
appetite, weight loss and sleep disturbance [19, 164, 165].
Long-acting formulations of MPH have been developed to
allow once-daily dosing. However, long-acting MPH does
not provide 24-h coverage [166], so some children/ado-
lescents may experience troublesome symptoms of ADHD
during the evening, night or early morning. In addition,
recent work has shown that MPH causes chronic changes to
pyramidal neuron function and synaptic plasticity in the
juvenile rat PFC [167, 168], and the implication of these
findings on human neurodevelopment remains unknown.
Early PET evidence also suggests that long-term MPH
therapy upregulates DATs in the striatum; this could
reduce treatment efficacy and lead to ADHD symptom
rebound on drug cessation, including during drug holidays
[169]. As such, some clinicians may seek alternative
treatment options for their patients.
5 Clinical Considerations on GXR
GXR directly stimulates a2A-adrenergic receptors and,
according to the HCN channel and network hypotheses,
thereby improves the ‘signal-to-noise’ ratio in the PFC.
The selective effects of GXR may translate into clinical
benefit for patients who require an alternative pharma-
cotherapy for ADHD. GXR is readily absorbed after oral
ingestion and exhibits a linear PK profile in children and
adults [137, 138]. Peak plasma concentration is achieved
approximately 5 h after oral administration of a single dose
of GXR [137, 170] and it has a long excretion half-life (of
approximately 17 h) in adults [137]. Thus, the prolonged-
release tablets provide a broad and flat GXR concentration
profile [137, 138] that allows once-daily dosing [171].
GXR is bound moderately (70 %) to plasma proteins and
metabolized primarily by cytochrome P450 (CYP) 3A4;
plasma levels are affected by CYP3A4/5 inducers and
inhibitors, such as ketoconazole [26].
5.1 Clinical Data on GXR in ADHD
Clinical trial data show that GXR is effective for the treat-
ment of children and adolescents with ADHD as
monotherapy or when administered as adjunctive therapy
with stimulants [172–179]. Pivotal trial data on GXR are
summarized in Table 2. Once-daily GXR significantly
reduces ADHD core symptoms versus placebo among
patients aged 6–17 years, and improvement is observed
within 2 weeks of starting GXR treatment [173, 176, 177].
A significant improvement in functional outcomes (includ-
ing Clinical Global Impressions of Improvement scale and
Weiss Functional Impairment Rating Scale-Parent Report
domains) with GXR was also observed in clinical trials [175,
177, 180]. The effect size of GXR monotherapy on ADHD
Rating Scale version IV (ADHD-RS-IV) symptom scores in
double-blind, placebo-controlled, pivotal trials ranges from
0.43 to 0.86 (Table 2). This is lower than the effect size of
stimulants but similar to that reported for ATX (0.59–0.67)
[15, 16, 23]. Head-to-head clinical direct comparison trial
data are not available and to our knowledge not currently
planned. Indirect comparisons, which must be interpreted
cautiously in general, suggest that GXR may confer greater
ADHD symptom control than does ATX [177, 181]. How-
ever, indirect comparisons should be replicated or supported
by direct comparisons before being taken as scientific basis
for clinical decision making.
GXR has a broad, smooth and sustained concentration
profile (that contrasts with the variable plasma levels
associated with long-acting MPH) [137, 138, 166].
Administration of GXR in either the morning or evening is
associated with significant and clinically meaningful
improvements in ADHD symptoms (Fig. 5) [179]. At least
10–12 weeks of ATX treatment are required to achieve a
full response [24]. Data suggest that GXR has a faster onset
of efficacy than does ATX (significant placebo-adjusted
improvement in ADHD-RS-IV total score observed at
Week 1 and Week 3, respectively), although findings
should be interpreted cautiously as this study was not
designed or powered to compare active treatments [177].
The safety and tolerability of GXR have been well
established in clinical trials and post-marketing experience
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in Canada and the USA. Treatment with GXR seems to be
generally well tolerated [173, 177]. The most frequently
reported adverse events associated with GXR in an open-
label extension study were somnolence (30.4 %), headache
(26.3 %), fatigue (14.2 %) and sedation (13.3 %) [172].
Somnolence/sedation (6 %) and fatigue (2 %) were the
most common adverse reactions leading to discontinuation
of GXR monotherapy from two large USA studies [173,
176]. Indeed, dose-dependent sedative effects are well
described but tend to be transient [172, 173, 175, 182].
GXR is associated with modest dose-dependent reduc-
tions in blood pressure and heart rate but hypotension and
bradycardia may occur [26, 173, 175]. Cardiovascular
effects are reported most frequently in the first month of
treatment [172, 173]. Transient hypertension following
abrupt discontinuation of GXR has also been reported so
the dose should be tapered gradually in decrements of no
more than 1 mg every 3–7 days [26, 27]. GXR is associ-
ated with QT/QTc prolongation; however, it has a stabi-
lizing effect on cardiac restitution, in line with a lack of
arrhythmia liability [183, 184].
GXR is associated with growth that is similar to nor-
mative data [26]. ATX carries a black box warning of
suicidal ideation [185, 186] but, reassuringly, there are no
reports to date of an increased risk of suicide-related
behaviour with GXR. Additional information on con-
traindications, precautions and adverse reactions associated
with GXR is available in the Summary of Product
Characteristics as reviewed by the European Medicines
Agency [28].
5.2 Practical Applications of GXR in ADHD
Clinical Practice
Because of its distinct mode of action, GXR may offer a
particularly useful alternative treatment option for specific
patient populations. The prevalence of ADHD and some
commonly co-existing conditions are shown in Table 3. The
prevalence of most individual co-morbid conditions among
patients with ADHD is relatively low but, when considered
together, represents a sizable population with substantial
impairment that may be poorly managed using stimulants
alone. Clinical efficacy and safety data support the use of
GXR among patients with a suboptimal response to stimu-
lants, chronic tic disorders (including Tourette’s syndrome)
and/or ODD (or oppositional symptoms; Table 4).
5.2.1 Suboptimal Response to Stimulants
GXR is approved for the treatment of ADHD as adjunctive
therapy to stimulant medications in Canada and the USA
(for children and adolescents). In an open-label trial of
children/adolescents with a suboptimal response to long-
acting MPH or amphetamine monotherapy, adjunctive
GXR was associated with improvement in ADHD symp-
tom scores from baseline (Table 4) [187]. These results
were validated in a randomized controlled trial (RCT) of
children/adolescents with suboptimal response to long-
acting MPH or amphetamines, in which adjunctive GXR
significantly improved ADHD symptom scores versus
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All-active GXR AM GXR PM Placebo
Fig. 5 Guanfacine extended release (GXR) monotherapy adminis-
tered in either the morning or evening improves attention-deficit
hyperactivity disorder (ADHD) symptoms. Mean change from
baseline in ADHD Rating Scale version IV (ADHD-RS-IV) total
score among patients receiving GXR. p values based on type III sum
of squares from an analysis of covariance model. ap\ 0.05 vs.
placebo based on change from baseline (Visit 2). cp\ 0.001 vs.
placebo based on change from baseline (Visit 2). Reproduced with
permission from Newcorn et al. Randomized, double-blind trial of
guanfacine extended release in children with attention-deficit/hyper-
activity disorder: morning or evening administration. J Am Acad
Child Adolesc Psychiatry. 2013;52:921–30.  (2013) with permission
from Elsevier. LOCF last observation carried forward, LS least
squares, SEM standard error of the mean
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specified subgroup analysis of phase III trial data, GXR
monotherapy was associated with a significant improve-
ment in ADHD-RS-IV total scores in both prior-MPH-
treated and stimulant-naı¨ve children/adolescents (Table 4),
whereas ATX was associated with a significant improve-
ment in ADHD-RS-IV total scores in stimulant-naı¨ve
patients only (RCT data only; difference in least squares
mean vs. placebo: -5.0 [p = 0.022] and -1.8
[p = 0.452]) [188]. Appropriately designed randomized
studies are needed to confirm the findings of these sub-
group analyses and further support treatment sequencing
decisions for individuals with ADHD.
5.2.2 Tics and Related Problems
Some patients with tic disorders benefit from stimulant
medication, as improved concentration can suppress tics;
however, others may find that tics are induced or exacer-
bated [189]. The benefit of a2-adrenergic receptor agonists
on both ADHD and co-morbid tic disorders has been
demonstrated in a number of studies [190–193]. Guan-
facine was effective in reducing tics in two small studies of
children with ADHD and co-morbid tic disorders (Table 4)
[194, 195]. A systematic review and meta-analysis of data
from RCTs (n = 6) demonstrated benefit of a2-adrenergic
receptor agonists in treating tics among patients with
ADHD [196]. At present, the use of GXR/guanfacine for
tic disorders in children/adolescents is strongly recom-
mended in Canadian, but not European, treatment guide-
lines [197, 198].
5.2.3 Emotional Dysregulation and Oppositional Defiant
Disorder (ODD) Problems
Emotional dysregulation is a common feature of ADHD
and is also present in other psychiatric disorders [8, 9].
Dysfunction of a neural network comprising the orbito-
frontal cortex, ventral striatum and amygdala is implicated
in emotional dysregulation [8]. Guanfacine modulates
emotional responses [119] and has been shown to reduce
feelings of frustration among children with ADHD [199].
GXR (vs. placebo) significantly reduced oppositional
symptoms among children aged 6–12 years with ADHD
and co-morbid oppositional symptoms [174], and was
associated with significantly greater reduction in opposi-
tional subscale scores than was ATX (p = 0.01; Table 4)
[200]. Furthermore, adjunctive GXR significantly reduced
oppositional symptoms among children/adolescents (aged
6–17 years) with ADHD and oppositional symptoms
(Table 4) [201]. It has been postulated that GXR reduces
symptoms of aggression by strengthening orbitofrontal
cortical regulation of emotion [29]. GXR could offer a
useful treatment option for patients with ADHD who
experience severe impairment due to emotional
dysregulation.
5.2.4 Intolerable Side Effects of Stimulants
GXR could hypothetically benefit other specific popula-
tions of patients with ADHD, as inferred by its distinct
mode of action. This may include patients who experience
Table 3 Prevalence of attention-deficit/hyperactivity disorder (ADHD) and some commonly co-existing conditions for which stimulants are not
suitable, not tolerated or have been shown to be ineffective
Range of prevalence of condition among
patients with ADHD
Range of prevalence of ADHD among patients
with condition
Stimulants associated with a suboptimal response, contraindicated or potentially unsuitable
Suboptimal response to stimulant 11–44 % [144, 232–236] N/A
Intolerant of stimulant side-effects 2–8 % [235, 237] N/A
Chronic tic disorders (including
Tourette’s syndrome)
1–33 % [10, 238–246] 11–73 % [241, 243, 244, 247–251]
Cardiovascular disorders (including
hypertension and tachycardia)
No data found 70 % in HLHS [252]
Problems relating to emotional regulation and impulse control
Emotional dysregulation 11–66 % [253–258] No data found
Oppositional defiant disorder 12–67 % [10, 238–240, 242, 243, 245, 259–
264]
30 % [243]
Conduct disorder 5–46 % [10, 238–240, 243, 245, 246, 260–264] 40 % [243]
Addictive behaviour
Eating disorders 1–16 % [239, 243, 245, 265, 266] 10 % [243]
Substance abuse/dependence 2–16 % [238, 239, 245, 262, 267] 54 % (children) [268]
18–31 % (adolescents) [268, 269]
HLHS hypoplastic left heart syndrome, N/A not applicable
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intolerable side effects of stimulant medications. Weight
loss is a commonly reported side effect of stimulants, and
ADHD per se may also be associated with dysregulated
growth [202, 203]. Clinicians may prefer to avoid using
stimulants among patients with pre-existing low body mass
index, as even relatively minor stimulant-related weight
reduction may be associated with long-term changes in
body composition [204]. In such cases, using, or switching
to, a non-stimulant medication can provide a helpful
alternative management strategy [205].
5.2.5 Hypertension or Other Cardiovascular Disorders
Juvenile hypertension is being increasingly recognized as
an important public health issue [206–208]. Hypertension is
estimated to affect up to 6 % of children and adolescents
and up to 40 % of those who are overweight or obese [206,
209]. Stimulants and ATX have sympathomimetic effects
on the cardiovascular system, including small but signifi-
cant increases in blood pressure and heart rate [25].
Accordingly, stimulants and ATX are contraindicated for
patients with underlying cardiovascular disorders that could
be compromised by an increase in blood pressure or heart
rate [186, 210]. Thus, a thorough history and examination
are required prior to initiation of stimulant treatment to
exclude a personal or family history of cardiovascular dis-
orders [2, 186]. GXR does not cause hypertension or affect
cardiac re-polarization but may reduce heart rate and blood
pressure [131]. Thus, children/adolescents with ADHD and
co-existing tachycardia, juvenile hypertension (or prehyper-
tension) or other cardiovascular symptoms could potentially
benefit from GXR [189].
5.2.6 Substance Use Disorder and Impulsivity Problems
Children, and adolescents in particular, who have ADHD
are impulsive and novelty seeking, and therefore are
inherently at higher risk of substance use disorder (SUD)
[2, 211]. Unlike stimulants, GXR (and ATX) does not
stimulate the nucleus accumbens, which is involved in the
regulation of reward-related behaviour [122, 212]. By
inference and despite a meta-analysis that demonstrated no
association between stimulant use and increased SUD risks
[213], GXR could provide a useful additional treatment
option for patients who are at particularly high risk of SUD,
unable to abstain from substance misuse despite stimulant
treatment, or those with family members who are known to
misuse drugs. Indeed, guanfacine has been shown to
improve resistance to impulsive behaviour in a primate
model and human studies [97, 214]. ADHD is a risk factor
for children being obese or overweight [215], and dysreg-
ulated, impulsive over-eating behaviours are believed to
contribute to weight gain [216]. Thus, GXR could
theoretically offer a beneficial treatment option for patients
with ADHD and associated obesity related to impulsive
over-eating.
5.2.7 Circadian Cycle and/or Sleep Problems
The use of GXR to target specific periods of the circadian
cycle may be a key application in clinical practice. The
early morning routine can be a particularly challenging
time of day for families of children with ADHD [217].
Our clinical experience suggests that executive functional
deficit resulting in disorganized or oppositional behaviour
before the morning dose of ADHD medication is a
common and severely disruptive problem. Recent data
suggest that GXR administered in the morning may result
in a reduced total sleep time versus placebo among
children with ADHD and pre-existing sleep problems
(-57 vs. ?31 min; p = 0.005) [218]. The author suggests
a possible link between reduced sleep time with GXR and
daytime somnolence [218]; however, as this study was
terminated early and thus lacks sufficient statistical
power, it should be considered as preliminary evidence
that needs further investigation. Stimulants in particular
may cause sleep disturbances if administered in the eve-
ning so should be administered at this time only very
cautiously [19, 219], whereas GXR can be administered
either in the morning or in the evening [179]. The mode
of action of GXR infers that administration in the evening
could help children with ADHD to sleep and wake up
relatively symptom-free. Indeed, recent data show that
morning or evening administration of GXR significantly
improves ADHD-related symptoms in the morning and
throughout the day (as assessed by modified Connors’
Parent Rating Scale–Revised: Short Form total scores;
p\ 0.001 vs. placebo at Week 8 regardless of the time of
GXR administration) [220]. GXR administered in the
morning or evening adjunctively with a psychostimulant
is also associated with improvement in morning symp-
toms of ADHD [180].
5.3 Other Potential Clinical Applications of GXR
Previous studies also suggest that GXR, through its specific
mode of action on the PFC, could offer an effective therapy
for conditions other than ADHD. Post-traumatic stress
disorder (PTSD) is associated with excessive noradrenaline
release [221] and PFC dysfunction may contribute to the
inadequate inhibition of traumatic memories [221]. Indeed,
there is substantial symptom overlap and co-morbidity
between ADHD and PTSD [222]. Rat studies have shown
that guanfacine reverses stress-induced PFC deficits while
not exacerbating conditioned fear [112, 223]. Moreover,
GXR (1–4 mg administered once daily) was found to
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reduce the severity of traumatic stress symptoms among
children/adolescents in an open-label pilot study [224].
a2A-Adrenergic receptor agonists, including guan-
facine, have also been studied in other PFC-associated
cognitive disorders. Early data suggest that guanfacine may
have beneficial effects in the treatment of attention disor-
ders associated with neurological conditions [225–227].
Improvement with guanfacine has been reported among
selected patients who have mild traumatic brain injury,
visual neglect following stroke, and deficits in arousal and
sustained attention following acute disseminated
encephalomyelitis [225–227]. In a rat study, guanfacine
has been reported to prevent hypobaric hypoxia-induced
spatial working memory deficits and neurodegeneration
[228]. The results suggest a potential role for GXR in
improving prefrontal cognitive function during high alti-
tude exposure [228].
6 Future Perspectives
Further research into the pathophysiology and aetiological
heterogeneity of ADHD and the modes of action of
effective pharmacotherapies will increase the use of indi-
vidualized patient management strategies [229]. The
identification of patients with ADHD who are likely to
respond to specific treatments and/or avoid side effects
using baseline demographic or clinical characteristics (in-
cluding co-morbidities and adverse reaction profiles) could
improve outcomes [230]. Matching individual patients with
the most appropriate treatment strategy would help to
better address the needs of patients and their families and
improve the cost-effectiveness of care [230]. Advances in
the neurobiology of ADHD will also help to drive the
research and development of new therapeutic options.
7 Conclusions
This article provides an overview of recent advances in
neurobiology of ADHD and the mode of action of guan-
facine. An understanding of the neurobiology of ADHD
and available treatment options will help clinicians make
informed decisions to optimize the care of patients who
require an alternative pharmacotherapy. ADHD is a neu-
rodevelopmental disorder that affects synaptic transmission
and growth factors throughout the brain. Data from neu-
robiological studies and medication response patterns in
clinical trials support a key role for dopamine and nora-
drenaline in ADHD. Psychostimulants, and the non-stim-
ulant ATX, increase the extracellular availability of these
catecholamines at the synaptic cleft. Although stimulants
are the most widely prescribed treatment for ADHD, they
can be unsuitable for a sizable proportion of patients.
The selective a2A-adrenergic receptor agonist, GXR, is
an alternative non-stimulant ADHD pharmacotherapy.
According to the HCN channel and network hypotheses,
guanfacine acts directly on a2A-adrenergic receptors to
enhance noradrenaline neurotransmission. Animal studies
also provide preliminary evidence that guanfacine influ-
ences dendritic spine plasticity in the PFC. GXR is a new
non-stimulant pharmacotherapy for ADHD in Europe for
children and adolescents for whom stimulants are not
suitable, not tolerated or have been shown to be ineffective.
The selective mode of action of GXR may provide par-
ticular benefit for children/adolescents who have specific
comorbidities such as chronic tic disorders or ODD (or
oppositional symptoms) that have failed to respond to first-
line treatment options.
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